论文部分内容阅读
印度学者Mardikar等的MR PCI研究(高危PCI多中心注册研究)认为,高危PCI患者使用高剂量替罗非班优于依替巴肽,合用氯吡咯雷不能增强静脉GPⅡb/Ⅲa抑制剂的早期血小板抑制作用。适当的血小板抑制治疗可保护PCI患者,避免血栓事件发生。
The MR PCI study by the Indian scholar Mardikar et al. (High-risk PCI multicenter registry) concluded that high-dose tirofiban is superior to eptifibatide in patients with high-risk PCI and clopidogrel does not augment early platelet aggregation with intravenous GP IIb / IIIa inhibitors Inhibition. Appropriate platelet inhibition therapy can protect patients with PCI, to prevent thrombotic events.